Neoplasm of esophagus
Therapeutic area
Oncology
Rare disease
No
- Definition
- A neoplasm (disease) that involves the esophagus.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Neoplasm of esophagus
- Therapeutic area
- Oncology
- neoplasm of esophagus
- esophageal neoplasm
- esophageal neoplasms, benign and malignant
- esophageal tumor
- esophageal tumors
- esophageal tumour
- esophageal tumours
- esophagus neoplasm
- esophagus neoplasm (disease)
- esophagus tumor
- neoplasm of esophagus
- neoplasm of the esophagus
- neoplasm of the oesophagus
- oesophagus neoplasm
- oesophagus neoplasm (disease)
- oesophagus tumour
- tumor of esophagus
- tumor of the esophagus
- tumour of oesophagus
- tumour of the oesophagus
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0021355
- Parent condition
- MONDO:0003749
Related records
Broader conditions (11)
- Cancer or benign tumor
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Esophageal disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Upper digestive tract disorder
Narrower conditions (29)
- Barrett adenocarcinoma
- Benign neoplasm of esophagus
- Carcinoma of esophagus
- Carcinoma of esophagus, salivary gland type
- Esophageal adenocarcinoma
- Esophageal adenoid cystic carcinoma
- Esophageal adenosquamous carcinoma
- Esophageal basaloid carcinoma
- Esophageal cancer
- Esophageal granular cell tumor
- Esophageal lipoma
- Esophageal melanoma
- Esophageal neuroendocrine tumor
- Esophageal small cell neuroendocrine carcinoma
- Esophageal squamous cell carcinoma
- Esophagus carcinoma in situ
- Esophagus leiomyoma
- Esophagus leiomyosarcoma
- Esophagus liposarcoma
- Esophagus lymphoma
Trials (1,828)
- "Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillance is Stopped. The BLISS Project.
- [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
- 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
- 2D-radiotherapy in Palliation of Advanced Esophageal Cancer
- 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- 4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies
- 4D FDG PET in Esophageal Cancer
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- 99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma
- 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction
- A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
- A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
- A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Drugs in development (10)
- Avelumab Phase 2
- Camrelizumab Phase 3
- Cetuximab Phase 3
- Cisplatin Phase 3
- Docetaxel Phase 3
- Fluorouracil Phase 3
- Paclitaxel Phase 3
- Pembrolizumab Phase 3
- Tegafur Phase 3
- Uracil Phase 2
Other linked drugs (3)
- Catequentinib
- Povidone-iodine
- Zolbetuximab